Zacks Investment Research · Dec 15, 2023
Pharma Stock Roundup: PFE Issues Weak 2024 View, AZN to Buy Icosavax & More
Pfizer (PFE) issues a disappointing outlook for 2024. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax.
IC
NASDAQ · ICVX
Icosavax, Inc.
Healthcare · Biotechnology
$15.31
Down-$0.14 (-0.91%)
Updated Aug 16, 2026, 6:59 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 769.04M
- P/E ratio
- -6.88
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 8.56M
- Avg. volume
- 1.24M
Price performance
ICVX price history
1M range · 0 trading sessions · Daily adjusted prices
ICVX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ICVX news
The latest Smart Investors Daily articles mentioning ICVX.
Stock researchCompany · Overview
ICVX research
Overview
Company profile and research snapshot.
Company profile
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $27.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 2, 2024 | Guggenheim | Neutral | — |
| Nov 17, 2023 | Guggenheim | Buy | — |
| Oct 2, 2023 | Oppenheimer | Outperform | — |
| Apr 25, 2023 | Oppenheimer | Outperform | — |
| Jan 4, 2023 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Dec 13, 2023
Icosavax, Inc. (ICVX) Moves to Buy: Rationale Behind the Upgrade
Icosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research · Dec 13, 2023
Icosavax, Inc. (ICVX) Is Up 0.10% in One Week: What You Should Know
Does Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Benzinga · Dec 12, 2023
Crude Oil Down 4%; Aditxt Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Tuesday. The Dow traded up 0.32% to 36,520.57 while the NASDAQ rose 0.46% to 14,498.23. The S&P 500 also rose, gaining, 0.26% to 4,634.47. Check This Out: Microsoft, U.S. Bancorp And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Materials shares rose by 0.5% on Tuesday. In trading on Tuesday, energy shares fell by 1.7%. Top Headline Johnson Controls International plc (NYSE: JCI) reported weak results for its fourth quarter. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion (+2% organically), missing the consensus of $7.09 billion. Adjusted EPS of $1.05 (+6% Y/Y) below the consensus of $1.09, according to Benzinga Pro. Equities Trading UP Aditxt, Inc. (NASDAQ: ADTX) shares shot up 64% to $6.25. Aditxt agreed to acquire Evofem Biosciences in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million. Shares of C4 Therapeutics, Inc. (NASDAQ: CCCC) got a boost, surging 108% to $2.45. C4 Therapeutics entered into an exclusive license ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
